Previsioni

Il prezzo obiettivo medio degli analisti è +7,09€ (+30,57%). La mediana è +6,66€ (+22,65%).

Acquista	15
Mantieni	27
Vendi	0

Notizie Vai al feed delle notizie

Teladoc Health appoints Mark V. Anquillare to the board of directors

Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » Altro su de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply

Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » Altro su de.investing.com
Teladoc plunges about 24% after Q2 results and weak outlook

Teladoc reported a Q2 EPS loss of -$0.21 with revenue of $606.9 million, missing consensus. The Q3 outlook of $569–609 million is well below the $629 million consensus, and the full-year loss forecast was lowered to -$1.00 to -$0.75. The combination of a revenue miss, reduced guidance and continued drag from the BetterHelp segment triggered the sharp share decline. Investors are now awaiting management comments on the conference call for signs of a return to revenue growth. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Teladoc Health ha già distribuito 0,26€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Teladoc Health ha registrato ricavi pari a 531,80 Mio€ e un utile netto di −34,09 Mio€

(EUR)	giu 2026	YoY
Ricavi	+531,80 Mio	0,81%
Utile lordo	+545,08 Mio	45,56%
Utile netto	−34,09 Mio	23,03%
EBITDA	−109,12 Mio	4.907,89%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+968,36 Mio€
Numero di azioni	181,68 Mio
Massimo/minimo a 52 settimane	+8,49€ - +3,78€
Dividendi	No
Beta	2,13
Rapporto P/E	−6,27
Rapporto PEG	−0,38
Rapporto P/B	+0,85
Rapporto P/S	+0,45

Profilo aziendale

Teladoc Health, Inc. bietet virtuelle Gesundheitsdienste in den Vereinigten Staaten und international an. Das Unternehmen bietet ein Portfolio von Dienstleistungen und Lösungen für nicht dringende, episodische, chronische und komplizierte medizinische Erkrankungen, einschließlich Diabetes, Bluthochdruck, chronische Nierenerkrankungen, Krebs, Herzinsuffizienz und psychische Erkrankungen. Das Unternehmen bietet eine Reihe von Programmen und Dienstleistungen an, darunter Lösungen für die telemedizinische Grund- und Spezialversorgung, das Management chronischer Erkrankungen, medizinische Expertendienste, Lösungen für psychische Erkrankungen sowie Plattform- und Programmdienste. Das Unternehmen bedient Arbeitgeber, Gesundheitspläne, Krankenhäuser und Gesundheitssysteme, Versicherungs- und Finanzdienstleistungsunternehmen sowie Einzelmitglieder. Es bietet seine Produkte und Dienstleistungen unter den Marken Teladoc, Livongo und BetterHelp an. Das Unternehmen war früher als Teladoc, Inc. bekannt und änderte im August 2018 seinen Namen in Teladoc Health, Inc. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Purchase, New York.

Nome	Teladoc Health
CEO	Charles Divita
Sede centrale	New York, ny Stati Uniti
Sito web	teladochealth.com
Settore	Sanità
Industria	Fornitori e servizi sanitari
Quotazione in borsa	30/06/2015
Dipendenti	5.124